Sopharma AD Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Sopharma AD ha aumentado sus beneficios a una tasa media anual de 14.8%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 8.6% anual. Los ingresos han ido creciendo a una tasa media de 9.2% al año. La rentabilidad financiera de Sopharma AD es de 11.9%, y sus márgenes netos son de 4.8%.

Información clave

11.7%

Tasa de crecimiento de los beneficios

10.8%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	12.4%
Tasa de crecimiento de los ingresos	9.2%
Rentabilidad financiera	10.0%
Margen neto	3.9%
Próxima actualización de resultados	30 Jan 2025

Actualizaciones de resultados anteriores recientes

Sopharma AD's (BUL:SFA) Problems Go Beyond Weak Profit

Sep 07

Recent updates

Desglose de ingresos y gastos

Cómo gana y gasta dinero Sopharma AD. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

BUL:SFA Ingresos, gastos y beneficios (BGN Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
30 Jun 24	1,974	78	280
31 Mar 24	1,932	93	265
31 Dec 23	1,888	95	255
30 Sep 23	1,832	81	242
30 Jun 23	1,787	91	233
31 Mar 23	1,742	83	224
31 Dec 22	1,672	71	216
30 Sep 22	1,651	107	223
30 Jun 22	1,655	101	223
31 Mar 22	1,629	92	222
31 Dec 21	1,611	89	225
30 Sep 21	1,608	58	225
30 Jun 21	1,527	41	219
31 Mar 21	1,460	37	214
31 Dec 20	1,446	30	213
30 Sep 20	1,375	75	194
30 Jun 20	1,353	85	201
31 Mar 20	1,340	82	200
31 Dec 19	1,288	87	196
30 Sep 19	1,257	35	200
30 Jun 19	1,231	30	191
31 Mar 19	1,209	31	192
31 Dec 18	1,188	28	187
30 Sep 18	1,166	34	183
30 Jun 18	1,125	32	178
31 Mar 18	1,077	35	166
31 Dec 17	1,024	40	158
30 Sep 17	965	52	149
30 Jun 17	930	53	142
31 Mar 17	906	57	142
31 Dec 16	883	51	139
30 Sep 16	874	29	140
30 Jun 16	867	21	141
31 Mar 16	878	23	138
31 Dec 15	883	21	141
30 Sep 15	883	24	145
30 Jun 15	877	29	143
31 Mar 15	860	17	141
31 Dec 14	852	20	142
30 Sep 14	833	19	135
30 Jun 14	811	19	136
31 Mar 14	793	24	134
31 Dec 13	767	29	128

Ingresos de calidad: SFA tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio(3.9%) de SFA son inferiores a los del año pasado (5.1%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de SFA han crecido un 14.8% al año en los últimos 5 años.

Acelerando crecimiento: SFA ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: SFA tuvo un crecimiento negativo de los beneficios (-14.9%) durante el año pasado, lo que dificulta la comparación con la media de la industria Pharmaceuticals (4.5%).

Sopharma AD Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Información clave

Actualizaciones de resultados anteriores recientes

Sopharma AD's (BUL:SFA) Problems Go Beyond Weak Profit

Second quarter 2024 earnings released: EPS: лв0.081 (vs лв0.26 in 2Q 2023)

First quarter 2024 earnings released: EPS: лв0.23 (vs лв0.27 in 1Q 2023)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Third quarter 2023 earnings released: EPS: лв0.12 (vs лв0.20 in 3Q 2022)

Sopharma AD to Report Q3, 2023 Results on Nov 29, 2023

Recent updates

Sopharma AD's (BUL:SFA) Problems Go Beyond Weak Profit

Second quarter 2024 earnings released: EPS: лв0.081 (vs лв0.26 in 2Q 2023)

Independent Director recently bought лв331k worth of stock

Chairman recently bought лв124k worth of stock

First quarter 2024 earnings released: EPS: лв0.23 (vs лв0.27 in 1Q 2023)

Here's Why Sopharma AD (BUL:SFA) Can Manage Its Debt Responsibly

Now 23% overvalued after recent price rise

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Chairman recently sold лв527k worth of stock

Sopharma AD, Annual General Meeting, Jun 30, 2024

Chairman recently bought лв338k worth of stock

New major risk - Financial position

Third quarter 2023 earnings released: EPS: лв0.12 (vs лв0.20 in 3Q 2022)

Upcoming dividend of лв0.90 per share at 8.4% yield

Sopharma AD Approves Distribution for the First Half of 2023, Payable on January 22, 2024

New minor risk - Share price stability

Sopharma AD to Report Q3, 2023 Results on Nov 29, 2023

New minor risk - Shareholder dilution

Chairman recently bought лв72k worth of stock

Investor sentiment improves as stock rises 17%

Sopharma AD to Report Q3, 2023 Results on Oct 30, 2023

Chairman recently bought лв81k worth of stock

Chairman recently sold лв1.1m worth of stock

Sopharma AD (BUL:SFA) acquired a 2.38% stake in Sopharma Buildings REIT-Sofia.

Second quarter 2023 earnings released: EPS: лв0.25 (vs лв0.19 in 2Q 2022)

New minor risk - Shareholder dilution

Sopharma AD (BUL:SFA) signed an agreement to acquire Pharmanova d.o.o.

Chairman recently sold лв297k worth of stock

New minor risk - Dividend sustainability

Upcoming dividend of лв0.60 per share

Sopharma AD Declares Dividend for 2022, Payable on 31 July 2023

First quarter 2023 earnings released: EPS: лв0.27 (vs лв0.17 in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations

Sopharma AD, Annual General Meeting, Jun 30, 2023

Sopharma AD to Report Fiscal Year 2023 Results on Mar 29, 2024

Consensus EPS estimates increase by 83%

Price target increased to лв4.83

Third quarter 2022 earnings released: EPS: лв0.20 (vs лв0.14 in 3Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: лв0.19 (vs лв0.12 in 2Q 2021)

Sopharma AD (BUL:SFA) made the offer to acquire remaining 66.66% stake in Sopharma Properties REIT (BUL:SFI) for approximately BGN 120 million.

First quarter 2022 earnings released: EPS: лв0.17 (vs лв0.14 in 1Q 2021)

Sopharma AD, Annual General Meeting, Jun 03, 2022

Less than half of directors are independent

Sopharma AD to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Sopharma AD to Report Fiscal Year 2021 Results on Mar 31, 2022

An unknown buyer has agreed to acquire SIA BRIZ from Sopharma AD (BUL:SFA).

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2021 earnings released

Chairman recently bought лв79k worth of stock

Price target decreased to лв3.48

Price target decreased to лв3.48

First quarter 2021 earnings released

Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance Sheet

Full year 2020 earnings released: EPS лв0.20 (vs лв0.69 in FY 2019)

New 90-day high: лв3.50

Here's Why We Think Sopharma AD (BUL:3JR) Is Well Worth Watching

How Many Sopharma AD (BUL:3JR) Shares Do Institutions Own?

Should You Rely On Sopharma AD's (BUL:3JR) Earnings Growth?

New 90-day high: лв3.26

Sopharma AD (BUL:3JR) acquired an unknown minority stake in SIA BRIZ.

Sopharma AD (BUL:3JR) Has A Somewhat Strained Balance Sheet

An unknown buyer acquired majority stake of Aromania OOD from Sopharma AD (BUL:3JR).

Sopharma AD (BUL:3JR) Share Prices Have Dropped 25% In The Last Three Years

New 90-day high: лв3.18

Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Are Investors Undervaluing Sopharma AD (BUL:3JR) By 29%?